Keywords
Asthma ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

463 Search results.

A Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of CAT-354 - Eligibility

- 5/22/15 - 1 form, 2 itemgroups, 27 items, 2 languages
Itemgroups: Inclusion Criteria, Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00640016

Safety, tolerability and pharmacodynamics of Elubrixin in cystic fibrosis patients, NCT00903201 - Asthma history

- 2/19/20 - 1 form, 2 itemgroups, 3 items, 1 language
Itemgroups: Administrative Data, Asthma history
Study ID: 110399 Clinical Study ID: 110399 Study Title: A randomized, double blind, parallel group, placebo controlled 28 day study to investigate the safety, tolerability and pharmacodynamics of SB-656933 in subjects with cystic fibrosis. Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00903201 https://clinicaltrials.gov/ct2/show/NCT00903201?term=NCT00903201 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: SB656933, Placebo Trade Name: N/A Study Indication: Cystic Fibrosis The study consists of a screening, five study visits and a follow-up (time relative to Baseline in days): Visit 1: Screening, Day -28 to -16 Visit 2a: Day -7 to -4 Visit 2b: Day 1 Visit 3: Day 14 Visit 4: Day 21 Visit 5: Day 28 Visit 6: Early Withdrawal/ Follow-up, Day 35 to 42. From day 1 to day 28 the patients will receive daily doses. This document contains the Asthma history form. It has to be filled in for screening.

Eligibility Eosinophilic Asthma NCT01290887

- 12/13/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01290887

Eligibility Difficult Asthma NCT01862289

- 11/23/19 - 1 form, 2 itemgroups, 14 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Prevalence of Hyperventilation Syndrome in Difficult Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01862289

A Parallel Group Study of Fluticasone Furoate/Vilanterol in Subjects with Asthma - 106837 - Concomitant Medications Form

- 10/30/19 - 1 form, 1 itemgroup, 22 items, 1 language
Itemgroup: Concomitant Medication Details
Study ID: 106837 Clinical Study ID: HZA106837 Study Title: A Long-Term, Randomized, Double-Blind, Parallel Group Study of Fluticasone Furoate/GW642444 Inhalation Powder Once-Daily and Fluticasone Furoate Inhalation Powder Once-Daily in Subjects with Asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01086384 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: fluticasone furoate/vilanterol Trade Name: Relvar Study Indication: Asthma

Eligibility Bronchial Asthma With eNO-levels Greater Than 30 ppB NCT01543516

- 10/21/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Cell Distribution in Induced Sputum in Patients With Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01543516

Eligibility Bronchial Asthma NCT01618929

- 10/21/19 - 1 form, 2 itemgroups, 20 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effects of Montelukast in Asthmatic Children With and Without Food Allergy; ODM derived from: https://clinicaltrials.gov/show/NCT01618929

Eligibility Bronchial Asthma NCT01455194

- 10/21/19 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect of High Dose Ciclesonide on Asthma Control; ODM derived from: https://clinicaltrials.gov/show/NCT01455194

Eligibility Bronchial Asthma NCT01414868

- 10/21/19 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Leukotriene D4 Bronchial Provocation Test (LTD4-BPT) as an Indicator for the Use of Leukotriene Receptor Antagonist (LTRA); ODM derived from: https://clinicaltrials.gov/show/NCT01414868

Eligibility Bronchial Asthma NCT01386151

- 10/21/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
A Study to Assess Safety and Efficacy of a Novel Treatment, Keratinocyte Growth Factor (KGF), in Asthmatic Patients; ODM derived from: https://clinicaltrials.gov/show/NCT01386151

Eligibility Bronchial Asthma NCT01113437

- 10/21/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Criteria, Exclusion Criteria
Omalizumab in Non-atopic Asthma; ODM derived from: https://clinicaltrials.gov/show/NCT01113437

Eligibility Bronchial Asthma NCT01759472

- 10/7/19 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Effect Study of Montelukast to Treat Asthma Detected by LTD4 Bronchial Provocation Test; ODM derived from: https://clinicaltrials.gov/show/NCT01759472